ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a phase Ib/II open-label non-randomised clinical trial

Davies, Andrew; Ardeshna, Kirit; Barrans, Sharon; burton, cathy; Caddy, Joshua; Chinnery, Fay; Collins, Graham; Day, Laura; Fernando, Diana; Johnson, Peter; McMillan, Andrew; Mercer, Katy; Radford, John; Rule, Simon; Griffiths, Gareth O.

doi:10.6084/m9.figshare.11791275.v4

ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a phase Ib/II open-label non-randomised clinical trial

journal contribution

posted on 2020-02-12, 15:14 authored by Andrew Davies, Kirit Ardeshna, Sharon Barrans, cathy burton, Joshua Caddy, Fay ChinneryFay Chinnery, Graham Collins, Laura Day, Diana Fernando, Peter Johnson, Andrew McMillan, Katy Mercer, John Radford, Simon Rule, Gareth O. Griffiths

Protocol, Informed consent forms and SPIRIT checklist for the ACCEPT trial.